You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創勝集團-B(06628.HK)夥百時美施貴寶拓治療胃癌臨牀試驗
創勝集團-B(06628.HK)公佈,已與百時美施貴寶建立全球臨牀合作開展TST001(公司開發的一種靶向Claudin18.2的在研人源化單克隆抗體),聯合歐狄沃(納武利尤單抗)(百時美施貴寶的抗PD-1療法)用於治療不可切除局部晚期或轉移性胃癌或胃食管連接部癌(GC/GEJ)患者的全球臨牀試驗。 是次合作包括兩項開放、多中心、全球I/II期研究,一項在美國進行,一項在中國進行,以評估TST001聯合歐狄沃用於既往曾接受或未接受治療的不可切除局部晚期或轉移性Claudin18.2表達的胃癌/胃食管連接部癌患者的安全性、耐受性及抗腫瘤療效。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account